New vaccine aimed at Hard-to-Treat breast cancer enters human testing
NCT ID NCT05504707
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-phase trial tests an investigational vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). It is given directly into the tumor along with standard chemotherapy before surgery. The study includes 30 adults with early-stage triple-negative or ER-low breast cancer. The main goal is to find the safest dose and see if the combination improves treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.